Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $42
Benzinga Newsdesk 19 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $45 to $42.
Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $45 to $42.